Biocardia reports q3 loss per share $0.63

Biocardia reports 2019 third quarter financial results and business highlights.q3 revenue $194,000.qtrly net loss per share, basic & diluted $0.63.sees fda acceptance of cardiallo neurokinin-1 receptor positive mesenchymal stem cell ind application in q2 2020.

BCDA Ratings Summary

BCDA Quant Ranking